A Study ROP116991, Clinical Evaluation of 18 to 24mg/Day Ropinirole CR for Parkinson's Disease
Phase of Trial: Phase III
Latest Information Update: 18 Mar 2016
At a glance
- Drugs Ropinirole (Primary)
- Indications Parkinson's disease
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline
- 27 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 20 Jun 2014 Planned number of patients changed from 80 to 81 as reported by ClinicalTrials.gov record.